A practical reference on research chemical: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
== Technology == MA/MH technology is achieved by combining proprietary blends of polymers to obtain the desired MVTR and then manipulating the oxygen (O2) and carbon dioxide (CO2) transmission rates of the polymer by laser and/or mechanical microperforations. The result is a film which is tailored to provide the optimum modified atmosphere and modified humidity for the produce to be packaged. "Film composition and extent of microperforation are tailored in accordance with the respiratory activity and weight of the produce packaged, anticipated temperature fluctuations during storage and shipment, and expected physiological and pathological responses of the produce to CO2/O2 concentrations and humidity levels inside the package. ... [MA/MH] packaging allow[s] the formation of a desirable modified atmosphere, retarding ripening and senescence of the produce. Additional beneficial effects ... include reduction of decay, chilling injury, leaf elongation, leaf sprouting, tissue discoloration, peel blemishes, and formation of off-odors, and inhibition of bacterial growth on the produce surface."
=== March === March 4, 2009: Canada U.S. Steel announced the closure of the Stelco Lake Erie Works in Nanticoke, Ontario due to the increasingly worse effects of the global economic slowdown. While it may have decreased the local pollution levels, it also has affected 12,000 jobs both at the Lake Erie Works and in the Haldimand-Norfolk area.
Joyanti Chutia is an Indian physicist who specializes in solid-state physics and plasma physics. She was among the first women who have headed scientific institutions in India when she became the director of the Institute of Advanced Study in Science and Technology in Guwahati, Assam, which is the first major research institution in North East India. She is a fellow of National Academy of Sciences. She is an emeritus scientist at the Department of Science & Technology in the Government of India.
has the effect of flattening out the distribution, similar to heating a metal. In such a distribution, it is easier to traverse between peaks (separated by valleys) than in the original distribution. After each iteration, a swap of states between two randomly chosen chains is proposed through a Metropolis-type step. Let
Sources: en.wikipedia.org
== Epidemiology == The prevalence of hemoglobin H disease mirrors that of the hemoglobinopathies. As a whole, they are most prevalent in individuals of Asian, African, and Mediterranean decent. There is a protective effect against malaria for individuals carrying thalassemia genes, which explains the high frequency of thalassemia within the worldwide population.
Malignant hyperthermia (MH) is a type of severe reaction that occurs in response to particular medications used during general anesthesia, among those who are susceptible. Symptoms include muscle rigidity, fever, and a fast heart rate. Complications can include muscle breakdown and high blood potassium. Most people who are susceptible to MH are generally unaffected when not exposed to triggering agents. Exposure to triggering agents (certain volatile anesthetic agents or succinylcholine) can lead to the development of MH in those who are susceptible. Susceptibility can occur due to at least six genetic mutations, with the most common one being of the RYR1 gene. These genetic variations are often inherited in an autosomal dominant manner. The condition may also occur as a new mutation or be associated with a number of inherited muscle diseases, such as central core disease. In susceptible individuals, the medications induce the release of stored calcium ions within muscle cells. The resulting increase in calcium concentrations within the cells cause the muscle fibers to contract. This generates excessive heat and results in metabolic acidosis. Diagnosis is based on symptoms in the appropriate situation. Family members may be tested to see if they are susceptible by muscle biopsy or genetic testing. Treatment is with dantrolene and rapid cooling along with other supportive measures. The avoidance of potential triggers is recommended in susceptible people. The condition affects one in 5,000 to 50,000 cases where people are given anesthetic gases.
Women in the forest camps were forbidden from entering combat, but often trained in first aid, communication/propaganda, and recruitment tactics. The Huks enjoyed early successes with their continuous attacks, aimed at raising morale through quick successes as well as to acquire weapons for the severely unarmed group. The Japanese conducted two counterattacks against the Huks, on September 6 and December 5, 1942. Both attacks did nothing to dampen the frequency of Huk raids, and only served to intensify Huk operations. On March 5, 1943, the Japanese struck the Huk headquarters in Cabiao, Nueva Ecija in a surprise attack. A large number of CPP cadres and Huk soldiers were captured during the raid. By the end of the war, the Huks had 1,200 engagements, and inflicted some 25,000 enemy casualties. The Huks' strength consisted of 20,000 fully armed regulars and some 50,000 reservists.
Sources: en.wikipedia.org
Joullié (born 1927), Brazilian, American organic chemist Isabella Karle (1921–2017), American crystallographer Joyce Jacobson Kaufman (1929–2016), American chemist, Pharmacologist Judith Klinman (born 1941), American biochemist Teresa Kowalska (1946-2023), Polish chemist, co-founder of Acta Chromatographia Marisa Kozlowski, American organic chemist Stephanie Kwolek (1923–2014), American chemist, inventor of Kevlar Sine Larsen (1943–2025), Danish structural chemist and crystallographer Kathleen Lonsdale (1903–1971), British crystallographer Yvonne Connolly Martin (born 1936), American physical biochemist working on cheminformatics and computer-aided drug design in the US Marie Marynard Daly (1921–2001), First African American woman to earn her PhD in the United States Cynthia A.
The Mkhedrioni (Georgian: მხედრიონი, romanized: mkhedrioni) was a Georgian nationalist paramilitary organisation founded in 1989 by Jaba Ioseliani. It emerged during Georgia's transition to independence from the Soviet Union and played a major role in the Georgian Civil War and the War in Abkhazia. The Mkhedrioni was notorious for intimidation and criminal activities, including extortion, smuggling, robbery, and operating illegal roadblocks. It was banned by President Zviad Gamsakhurdia in 1991, regained influence after participating in the 1991–92 Georgian coup d'état that overthrew Gamsakhurdia, and was outlawed again in 1995 after the authorities accused Ioseliani and others of involvement in the attempted assassination of President Eduard Shevardnadze. After failing to secure registration to contest elections under its own name, it reconstituted itself as the Union of Patriots political party, which was also refused registration.
United States (US) US food safety regulations have set a maximum permitted level of 20 μg/kg for aflatoxin B1, in combination with the other aflatoxins (B2, G1 and G2) in all foods, with the exception of milk which has a maximum permitted level of 0.5 μg/kg. Higher levels of 100–300 μg/kg are tolerable for some animal feeds. European Union (EU) The EU has set maximum permitted levels for aflatoxin B1 in nuts, dried fruits, cereals and spices to range from 2–12 μg/kg, while the maximum permitted level for aflatoxin B1 in infant foods is set at 0.1 μg/kg. The maximum permitted levels for aflatoxin B1 in animal feeds set by the EU range from 5–50 μg/kg and these levels are much lower than those set in the US. Joint United Nations' Food and Agriculture Organization (FAO)/World Health Organization (WHO) Expert Committee on Food Additives (JECFA) The FAO/WHO JECFA has set the maximum permitted levels of aflatoxin B1 in combination with the other aflatoxins (B2, G1 and G2) to be 15 μg/kg in raw peanuts and 10 μg/kg in processed peanuts; while the tolerance level of aflatoxin B1 alone is 5 μg/kg for dairy cattle feed.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.